{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T02:24:33Z","timestamp":1769048673030,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P50DK114786"],"award-info":[{"award-number":["P50DK114786"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","award":["CRN-2020\u2013007"],"award-info":[{"award-number":["CRN-2020\u2013007"]}],"id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00467-025-06811-4","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T16:55:01Z","timestamp":1749142501000},"page":"3121-3127","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Utilization of anti-CD20 antibodies for treatment of childhood nephrotic syndrome, 2010 to 2022"],"prefix":"10.1007","volume":"40","author":[{"given":"Michelle R.","family":"Denburg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Hirabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy Goodwin","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanieh","family":"Razzaghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikas R.","family":"Dharnidharka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley P.","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph T.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline A.","family":"Gluck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark M.","family":"Mitsnefes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William E.","family":"Smoyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan L.","family":"Furth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher B.","family":"Forrest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"6811_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(18)30536-1","volume":"392","author":"DG Noone","year":"2018","unstructured":"Noone DG, Iijima K, Parekh R (2018) Idiopathic nephrotic syndrome in children. Lancet 392:61\u201374","journal-title":"Lancet"},{"key":"6811_CR2","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.ekir.2019.08.019","volume":"4","author":"GJ Oh","year":"2019","unstructured":"Oh GJ, Waldo A, Paez-Cruz F, Gipson PE, Pesenson A, Selewski DT, Kamil ES, Massengill SF, Lafayette RA, Modes M, Adler SG, Desmond H, Eikstadt R, Attalla S, Modi ZJ, Troost JP, Gipson DS (2019) Steroid-associated side effects in patients with primary proteinuric kidney disease. Kidney Int Rep 4:1608\u20131616","journal-title":"Kidney Int Rep"},{"key":"6811_CR3","doi-asserted-by":"publisher","unstructured":"Hahn D, Hodson EM, Willis NS, Craig JC (2020) Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev (8):CD001533. https:\/\/doi.org\/10.1002\/14651858","DOI":"10.1002\/14651858"},{"key":"6811_CR4","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00467-022-05739-3","volume":"38","author":"A Trautmann","year":"2023","unstructured":"Trautmann A, Boyer O, Hodson E, Bagga A, Gipson DS, Samuel S, Wetzels J, Alhasan K, Banerjee S, Bhimma R, Bonilla-Felix M, Cano F, Christian M, Hahn D, Kang HG, Nakanishi K, Safouh H, Trachtman H, Xu H, Cook W, Vivarelli M, Haffner D (2023) IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol 38:877\u2013919","journal-title":"Pediatr Nephrol"},{"key":"6811_CR5","doi-asserted-by":"publisher","unstructured":"Larkins NG, Liu ID, Willis NS, Craig JC, Hodson EM (2024) Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. Cochrane Database Syst Rev 11:CD002290. https:\/\/doi.org\/10.1002\/14651858","DOI":"10.1002\/14651858"},{"key":"6811_CR6","doi-asserted-by":"publisher","first-page":"710","DOI":"10.2215\/CJN.08500815","volume":"11","author":"P Ravani","year":"2016","unstructured":"Ravani P, Bonanni A, Rossi R, Caridi G, Ghiggeri GM (2016) Anti-CD20 antibodies for idiopathic nephrotic syndrome in children. Clin J Am Soc Nephrol 11:710\u2013720","journal-title":"Clin J Am Soc Nephrol"},{"key":"6811_CR7","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1001\/jamapediatrics.2020.6150","volume":"175","author":"P Ravani","year":"2021","unstructured":"Ravani P, Lugani F, Drovandi S, Caridi G, Angeletti A, Ghiggeri GM (2021) Rituximab vs low-dose mycophenolate mofetil in recurrence of steroid-dependent nephrotic syndrome in children and young adults: a randomized clinical trial. JAMA Pediatr 175:631\u2013632","journal-title":"JAMA Pediatr"},{"key":"6811_CR8","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamapediatrics.2018.1323","volume":"172","author":"B Basu","year":"2018","unstructured":"Basu B, Sander A, Roy B, Preussler S, Barua S, Mahapatra TKS, Schaefer F (2018) Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: a randomized clinical trial. JAMA Pediatr 172:757\u2013764","journal-title":"JAMA Pediatr"},{"key":"6811_CR9","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3389\/fped.2019.00178","volume":"7","author":"M Kallash","year":"2019","unstructured":"Kallash M, Smoyer WE, Mahan JD (2019) Rituximab use in the management of childhood nephrotic syndrome. Front Pediatr 7:178","journal-title":"Front Pediatr"},{"key":"6811_CR10","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1681\/ASN.2021040561","volume":"32","author":"P Ravani","year":"2021","unstructured":"Ravani P, Colucci M, Bruschi M, Vivarelli M, Cioni M, DiDonato A, Cravedi P, Lugani F, Antonini F, Prunotto M, Emma F, Angeletti A, Ghiggeri GM (2021) Human or chimeric monoclonal anti-CD20 antibodies for children with nephrotic syndrome: a superiority randomized trial. J Am Soc Nephrol 32:2652\u20132663","journal-title":"J Am Soc Nephrol"},{"key":"6811_CR11","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1681\/ASN.2019040365","volume":"30","author":"MR Denburg","year":"2019","unstructured":"Denburg MR, Razzaghi H, Bailey LC, Soranno DE, Pollack AH, Dharnidharka VR, Mitsnefes MM, Smoyer WE, Somers MJG, Zaritsky JJ, Flynn JT, Claes DJ, Dixon BP, Benton M, Mariani LH, Forrest CB, Furth SL (2019) Using electronic health record data to rapidly identify children with glomerular disease for clinical research. J Am Soc Nephrol 30:2427\u20132435","journal-title":"J Am Soc Nephrol"},{"key":"6811_CR12","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1136\/amiajnl-2014-002743","volume":"21","author":"CB Forrest","year":"2014","unstructured":"Forrest CB, Margolis PA, Bailey LC, Marsolo K, Del Beccaro MA, Finkelstein JA, Milov DE, Vieland VJ, Wolf BA, Yu FB, Kahn MG (2014) PEDSnet: a national pediatric learning health system. J Am Med Inform Assoc 21:602\u2013606","journal-title":"J Am Med Inform Assoc"},{"key":"6811_CR13","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1377\/hlthaff.2014.0127","volume":"33","author":"CB Forrest","year":"2014","unstructured":"Forrest CB, Margolis P, Seid M, Colletti RB (2014) PEDSnet: how a prototype pediatric learning health system is being expanded into a national network. Health Aff (Millwood) 33:1171\u20131177","journal-title":"Health Aff (Millwood)"},{"key":"6811_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2215\/CJN.07810621","volume":"17","author":"SE Wenderfer","year":"2022","unstructured":"Wenderfer SE, Chang JC, Goodwin Davies A, Luna IY, Scobell R, Sears C, Magella B, Mitsnefes M, Stotter BR, Dharnidharka VR, Nowicki KD, Dixon BP, Kelton M, Flynn JT, Gluck C, Kallash M, Smoyer WE, Knight A, Sule S, Razzaghi H, Bailey LC, Furth SL, Forrest CB, Denburg MR, Atkinson MA (2022) Using a multi-institutional pediatric learning health system to identify systemic lupus erythematosus and lupus nephritis: development and validation of computable phenotypes. Clin J Am Soc Nephrol 17:65\u201374","journal-title":"Clin J Am Soc Nephrol"},{"key":"6811_CR15","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1681\/ASN.2014080799","volume":"26","author":"P Ravani","year":"2015","unstructured":"Ravani P, Rossi R, Bonanni A, Quinn RR, Sica F, Bodria M, Pasini A, Montini G, Edefonti A, Belingheri M, De Giovanni D, Barbano G, Degl\u2019Innocenti L, Scolari F, Murer L, Reiser J, Fornoni A, Ghiggeri GM, (2015) Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial. J Am Soc Nephrol 26:2259\u20132266","journal-title":"J Am Soc Nephrol"},{"key":"6811_CR16","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s00467-020-04540-4","volume":"35","author":"P Ravani","year":"2020","unstructured":"Ravani P, Lugani F, Pisani I, Bodria M, Piaggio G, Bartolomeo D, Prunotto M, Ghiggeri GM (2020) Rituximab for very low dose steroid-dependent nephrotic syndrome in children: a randomized controlled study. Pediatr Nephrol 35:1437\u20131444","journal-title":"Pediatr Nephrol"},{"key":"6811_CR17","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.2215\/CJN.09421010","volume":"6","author":"P Ravani","year":"2011","unstructured":"Ravani P, Magnasco A, Edefonti A, Murer L, Rossi R, Ghio L, Benetti E, Scozzola F, Pasini A, Dallera N, Sica F, Belingheri M, Scolari F, Ghiggeri GM (2011) Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 6:1308\u20131315","journal-title":"Clin J Am Soc Nephrol"},{"key":"6811_CR18","doi-asserted-by":"publisher","first-page":"e13157","DOI":"10.1097\/MD.0000000000013157","volume":"97","author":"YH Ahn","year":"2018","unstructured":"Ahn YH, Kim SH, Han KH, Choi HJ, Cho H, Lee JW, Shin JI, Cho MH, Lee JH, Park YS, Ha IS, Cheong HI, Kim SY, Lee SJ, Kang HG (2018) Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: a multicenter open-label trial in Korea. Medicine (Baltimore) 97:e13157","journal-title":"Medicine (Baltimore)"},{"key":"6811_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaut.2017.10.006","volume":"88","author":"A Boumediene","year":"2018","unstructured":"Boumediene A, Vachin P, Sendeyo K, Oniszczuk J, Zhang SY, Henique C, Pawlak A, Audard V, Ollero M, Guigonis V, Sahali D (2018) NEPHRUTIX: a randomized, double-blind, placebo vs rituximab-controlled trial assessing T-cell subset changes in minimal change nephrotic syndrome. J Autoimmun 88:91\u2013102","journal-title":"J Autoimmun"},{"key":"6811_CR20","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y (2014) Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384:1273\u20131281","journal-title":"Lancet"},{"key":"6811_CR21","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.kint.2024.09.006","volume":"106","author":"V Raglianti","year":"2024","unstructured":"Raglianti V, Angelotti ML, Cirillo L, Ravaglia F, Landini S, Palazzo V, Melica ME, Antonelli G, Conte C, Buti E, Errichiello C, De Chiara L, Peired AJ, Lasagni L, Buccoliero AM, Allinovi M, Montero AM, Cruzado JM, Bruschi M, Ghiggeri GM, Angeletti A, Anders HJ, Lazzeri E, Mazzinghi B, Becherucci F, Romagnani P (2024) Anti-slit diaphragm antibodies on kidney biopsy identify pediatric patients with steroid-resistant nephrotic syndrome responsive to second-line immunosuppressants. Kidney Int 106:1124\u20131134","journal-title":"Kidney Int"},{"key":"6811_CR22","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa2314471","volume":"391","author":"FE Hengel","year":"2024","unstructured":"Hengel FE, Dehde S, Lass\u00e9 M, Zahner G, Seifert L, Schnarre A, Kretz O, Demir F, Pinnschmidt HO, Grahammer F, Lucas R, Mehner LM, Zimmermann T, Billing AM, Oh J, Mitrotti A, Pontrelli P, Debiec H, Dossier C, Colucci M, Emma F, Smoyer WE, Weins A, Schaefer F, Alachkar N, Diemert A, Hogan J, Hoxha E, Wiech T, Rinschen MM, Ronco P, Vivarelli M, Gesualdo L, Tomas NM, Huber TB (2024) Autoantibodies targeting nephrin in podocytopathies. N Engl J Med 391:422\u2013433","journal-title":"N Engl J Med"},{"key":"6811_CR23","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1681\/ASN.2021060794","volume":"33","author":"AJB Watts","year":"2022","unstructured":"Watts AJB, Keller KH, Lerner G, Rosales I, Collins AB, Sekulic M, Waikar SS, Chandraker A, Riella LV, Alexander MP, Troost JP, Chen J, Fermin D, Yee JL, Sampson MG, Beck LH Jr, Henderson JM, Greka A, Rennke HG, Weins A (2022) Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology. J Am Soc Nephrol 33:238\u2013252","journal-title":"J Am Soc Nephrol"},{"key":"6811_CR24","doi-asserted-by":"publisher","unstructured":"Hengel FE, Dehde S, Yilmaz A, Bayazit AK, Ozaltin F, Paripovic D, Emma F, Ronco P, Vivarelli M, Hogan J, Schaefer F, Tomas NM, Huber TB; PodoNet Consortium and the International Society of Glomerular Disease (2025) Anti-nephrin autoantibodies in steroid-resistant nephrotic syndrome may inform treatment strategy. Kidney Int. https:\/\/doi.org\/10.1016\/j.kint.2025.01.019","DOI":"10.1016\/j.kint.2025.01.019"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-06811-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-025-06811-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-06811-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T08:46:25Z","timestamp":1765874785000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-025-06811-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["6811"],"URL":"https:\/\/doi.org\/10.1007\/s00467-025-06811-4","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]},"assertion":[{"value":"3 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Dixon has consultancy agreements with Apellis Pharmaceuticals, Novartis Pharmaceuticals, Alexion Astra Zeneca Rare Disease, Arrowhead Pharmaceuticals, and Calliditas Therapeutics, and has received research funding from Apellis Pharmaceuticals, Novartis Pharmaceuticals, Alexion Astra Zeneca Rare Disease, Ultragenyx Pharmaceuticals, and Roche Genentech. The remaining authors have no relevant disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIDDK, the National Institutes of Health, the Department of Health and Human Services, or the government of the United States.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}